Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study

Next Previous
Trial Profile

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Ischaemia; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ALPHEUS

    • Most Recent Events

    • 01 Jan 2024 Results assessing the impact of the P2Y12 inhibitor loading time on periprocedural myocardial necrosis, published in the Canadian Journal of Cardiology
    • 28 Aug 2023 Results of post hoc analysis assessing the the frequency and outcomes of complex PCI in stable coronary patients and the efficacy of ticagrelor versus clopidogrel in these patients randomized in the ALPHEUS trial, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 28 Dec 2020 Results of meta-analysis comparing safety and efficacy of pP2Y12-I versus Clopidogrel in patients with CAD undergoing elective PCI published in the American Journal of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top